#United States #Los Angeles #Schall Law Firm #Intellia Therapeutics #NTLA

Investors Have a Chance to Take Action Against Intellia Therapeutics

In a significant development for stakeholders, the Schall Law Firm, renowned for representing investor rights, has announced a class action lawsuit against Intellia Therapeutics, Inc. (NASDAQ: NTLA). The lawsuit pertains to alleged violations of the Securities Exchange Act of 1934, specifically sections 10(b) and 20(a), along with the SEC Rule 10b-5. This follows accusations of disseminating false and misleading information to investors, impacting their investments during a specified period.

What Investors Need to Know

The class period for this lawsuit spans from July 30, 2024, to January 8, 2025. Investors who purchased Intellia's securities during this period are encouraged to take action and contact the Schall Law Firm before the deadline of April 14, 2025. Participating in this class action not only provides a platform for individuals to reclaim their losses but also sends a strong message regarding corporate accountability.

Background of the Allegations

The complaint outlined several critical points. It asserts that Intellia Therapeutics made misleading statements that portrayed a false sense of confidence regarding their drug candidate, NTLA-3001. The company suggested that it had robust information regarding the drug’s development and prospective market performance. However, it later became apparent that the timelines shared were neither feasible nor sustainable. This included issues with the delivery methods, which proved to be costly and inefficient, thus affecting the company’s ability to provide timely doses to patients and maintain an adequately staffed team.

When reality set in, and the market grasped the actual state of affairs, Intellia’s stock price suffered a significant downturn, leading many investors to incur substantial financial losses.

How to Get Involved

For shareholders who have experienced losses due to these alleged securities fraud activities, participation in this lawsuit offers a potential pathway to recovery. Interested parties are advised to contact Brian Schall of the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. The firm offers free consultations to discuss individual rights.

Investors can also reach out through the firm's official website or by email for more detailed information on how to participate.

It is crucial to note that the class has not yet been certified. Until such a certification occurs, individuals choosing to take no action will remain as uninterested party members.

The Firm’s Expertise

The Schall Law Firm has built a reputation for advocating on behalf of investors worldwide, focusing on securities fraud claims and protecting shareholder rights. This current lawsuit adds to a series of similar cases where shareholder rights are at stake, emphasizing the need for transparency and honesty from public companies.

Investors should not overlook this opportunity. Engaging with the Schall Law Firm might provide a route to financial remediation after suffering losses attributed to the alleged misrepresentation by Intellia Therapeutics.

For those looking to actively participate in this class action, contact Schall Law Firm promptly as the April deadline approaches. Together, investors can ensure their voices are heard and that corporate malfeasance does not go unchallenged.

• ---

For more detailed insights or to get started on your participation in this case, visit www.schallfirm.com or reach them directly at 310-301-3335. Don’t miss out on this important legal action related to Intellia Therapeutics.

• ---